The Evolution of Sarcoma Drug Sensitivity through Time and Space

肉瘤药物敏感性随时间和空间的演变

基本信息

项目摘要

PROJECT SUMMARY Approximately 16,000 people are diagnosed with sarcoma each year in the US. Sarcomas are the third most common cancer affecting children constituting about 15% of all diagnosed childhood tumors. Bone tumors are the rarest of all, with less than 3,500 cases a year or 0.2% of all cancers. Despite aggressive treatment, overall 5-year survival rates are ~60% and around 30% for metastatic disease. There is limited data on bone sarcoma drug sensitivity beyond first line chemotherapy. In parallel, there are major gaps in our understanding of sarcomas molecular hallmarks and drivers, with limited sequencing data available beyond the exome. Critically, very few sarcomas have had whole-genome sequencing, longitudinal profiling or multi-region sequencing to understand their spatio- and temporal-genomic variability. This variability is thought to be critical to understanding treatment response and failure, and there remains an urgent need to relate these molecular features to quantitative aspects of drug sensitivity in most tumor types. We have established a pipeline to develop personalized bone sarcoma organoids to screen hundreds of drugs and determine a drug resistance and sensitivity profile for each tumor. We pair this with whole-genome sequencing to identify mutational correlates of drug sensitivity. Here we will take advantage of this pipeline to study how the molecular and pharmacologic behavior of bone sarcomas differs spatially within a single patient (Aim 1) and how they vary during their transition from curable primary to lethal metastatic disease (Aim 2). This study will allow us to define how bone sarcoma metastases diverge and respond to therapy and identify actionable drug sensitivities as well as create a detailed portrait of how bone sarcomas evolve under therapeutic selective pressure, linked to clinical outcomes.
项目总结 在美国,每年约有16,000人被诊断为肉瘤。肉瘤排在第三位 影响儿童的常见癌症约占所有诊断的儿童肿瘤的15%。骨肿瘤是 最罕见的是,每年不到3500例,占所有癌症的0.2%。尽管接受了积极的治疗,但总的来说 5年生存率约为60%,转移性疾病约为30%。 除了一线化疗外,关于骨肉瘤药物敏感性的数据有限。同时,还有主要的 我们对肉瘤分子特征和驱动因素的理解存在差距,现有的测序数据有限 在序曲之外。关键的是,很少有肉瘤进行了全基因组测序、纵向分析或 多区域测序以了解它们的空间和时间基因组变异性。这种可变性被认为是 对理解治疗反应和失败至关重要,仍然迫切需要将它们联系起来 在大多数肿瘤类型中,从分子特征到药物敏感性的定量方面。 我们已经建立了一条开发个性化骨肉瘤有机化合物的管道,以筛选数百种药物 并确定每个肿瘤的耐药性和敏感性曲线。我们将其与全基因组配对 测序以确定药物敏感性的突变相关因素。在这里,我们将利用这条管道来 研究单个患者骨肉瘤的分子和药理学行为在空间上的差异 (目标1)以及它们在从可治愈的原发疾病向致命转移性疾病的转变过程中如何变化(目标2)。这 研究将使我们能够确定骨肉瘤转移是如何分化和对治疗做出反应的,并确定 可操作的药物敏感性,以及创建骨肉瘤如何在治疗下演变的详细描述 选择性压力,与临床结果有关。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Paul Christopher Boutros其他文献

Paul Christopher Boutros的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Paul Christopher Boutros', 18)}}的其他基金

Germline Determinants of Prostate Cancer Evolution
前列腺癌进化的种系决定因素
  • 批准号:
    10587968
  • 财政年份:
    2023
  • 资助金额:
    $ 48.7万
  • 项目类别:
Tool Core- Boutros
工具核心-Boutros
  • 批准号:
    10473401
  • 财政年份:
    2022
  • 资助金额:
    $ 48.7万
  • 项目类别:
Virginia-UCLA-Toronto Biomarker Characterization Center
弗吉尼亚-加州大学洛杉矶分校-多伦多生物标志物表征中心
  • 批准号:
    10696069
  • 财政年份:
    2022
  • 资助金额:
    $ 48.7万
  • 项目类别:
Randomized Trial of Exercise Therapy on Markers of Progression in Localized Prostate Cancer:
运动疗法对局限性前列腺癌进展标志物的随机试验:
  • 批准号:
    10705201
  • 财政年份:
    2022
  • 资助金额:
    $ 48.7万
  • 项目类别:
Core-Biomarker Development Laboratory
核心生物标志物开发实验室
  • 批准号:
    10696075
  • 财政年份:
    2022
  • 资助金额:
    $ 48.7万
  • 项目类别:
Tool Core- Boutros
工具核心-Boutros
  • 批准号:
    10655489
  • 财政年份:
    2022
  • 资助金额:
    $ 48.7万
  • 项目类别:
The Evolution of Sarcoma Drug Sensitivity through Time and Space
肉瘤药物敏感性随时间和空间的演变
  • 批准号:
    10202513
  • 财政年份:
    2020
  • 资助金额:
    $ 48.7万
  • 项目类别:
The Evolution of Sarcoma Drug Sensitivity through Time and Space
肉瘤药物敏感性随时间和空间的演变
  • 批准号:
    10778672
  • 财政年份:
    2020
  • 资助金额:
    $ 48.7万
  • 项目类别:
Signaling Drivers of Sarcoma Drug Resistance
肉瘤耐药性的信号驱动因素
  • 批准号:
    10437547
  • 财政年份:
    2020
  • 资助金额:
    $ 48.7万
  • 项目类别:
The Evolution of Sarcoma Drug Sensitivity through Time and Space
肉瘤药物敏感性随时间和空间的演变
  • 批准号:
    10646502
  • 财政年份:
    2020
  • 资助金额:
    $ 48.7万
  • 项目类别:

相似海外基金

Postdoctoral Fellowship: MPS-Ascend: Coarse-Grained Modeling of Aggrecan- Mimetic Copolymers: Polymer Design and Architecture Effects on Structure and Phase Behavior
博士后奖学金:MPS-Ascend:聚集蛋白聚糖模拟共聚物的粗粒度建模:聚合物设计和结构对结构和相行为的影响
  • 批准号:
    2316666
  • 财政年份:
    2023
  • 资助金额:
    $ 48.7万
  • 项目类别:
    Fellowship Award
Conference: 2023 Neuroethology: Behavior, Evolution and Neurobiology GRC Linking Diversity in Cells, Circuits, and Brain Architecture to Ecologically Relevant Behaviors
会议:2023 年神经行为学:行为、进化和神经生物学 GRC 将细胞、回路和大脑结构的多样性与生态相关行为联系起来
  • 批准号:
    2334509
  • 财政年份:
    2023
  • 资助金额:
    $ 48.7万
  • 项目类别:
    Standard Grant
Architecture, dynamics and cell-specific behavior of tau condensates
tau 凝聚物的结构、动力学和细胞特异性行为
  • 批准号:
    10662730
  • 财政年份:
    2023
  • 资助金额:
    $ 48.7万
  • 项目类别:
NSF-BSF: Natural selection on the social interactions that mediate collective behavior: ecological pressures and genomic architecture
NSF-BSF:介导集体行为的社会互动的自然选择:生态压力和基因组结构
  • 批准号:
    1940647
  • 财政年份:
    2020
  • 资助金额:
    $ 48.7万
  • 项目类别:
    Continuing Grant
Description method and formal verification method with section behavior model based on software architecture
基于软件体系结构的分段行为模型描述方法和形式化验证方法
  • 批准号:
    19K11911
  • 财政年份:
    2019
  • 资助金额:
    $ 48.7万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Investigation of the influence of architecture and doping of diamond like carbon coatings on the damage behavior under cyclic mechanical stress
研究类金刚石碳涂层的结构和掺杂对循环机械应力下损伤行为的影响
  • 批准号:
    279491470
  • 财政年份:
    2015
  • 资助金额:
    $ 48.7万
  • 项目类别:
    Research Grants
CAREER: Genetic Architecture and Proximate Mechanisms Underlying Indirect Genetic Effects on Cooperative Antipredator Behavior
职业:间接遗传效应对合作性反捕食者行为的遗传结构和直接机制
  • 批准号:
    1453536
  • 财政年份:
    2015
  • 资助金额:
    $ 48.7万
  • 项目类别:
    Continuing Grant
The Genetic Architecture of Aggressive Behavior
攻击行为的遗传结构
  • 批准号:
    6935104
  • 财政年份:
    2005
  • 资助金额:
    $ 48.7万
  • 项目类别:
The Genetic Architecture of Aggressive Behavior
攻击行为的遗传结构
  • 批准号:
    7246470
  • 财政年份:
    2005
  • 资助金额:
    $ 48.7万
  • 项目类别:
The Genetic Architecture of Aggressive Behavior
攻击行为的遗传结构
  • 批准号:
    7065220
  • 财政年份:
    2005
  • 资助金额:
    $ 48.7万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了